Oxford Immunotec Global Plc (OXFD) Growth Rates Comparisons to In Vitro & In Vivo Diagnostic Substances Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Suppliers, else..
 
Oxford Immunotec Global Plc  (NASDAQ: OXFD)
 

Oxford Immunotec Global Plc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OXFD Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) -8.4 % 40.37 % 10.98 % -2.03 %
Q / Q Revenue Growth (Q3 MRQ) 233.09 % 36.27 % 15.57 % 13.28 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) -19.26 % 14.07 % 6.95 % -3.2 %
Sequential Revenue Growth (for 12 months ending Q3 TTM) -3.02 % 9.85 % 2.33 % -0.52 %
Revenue 5 Year Average Growth 8.29 % 10.75 % 9.18 % 10.19 %


OXFD's Growth Comparisons in III. Quarter 2020




Although the In Vitro & In Vivo Diagnostic Substances industry saw advancing Revenue by 40.37%, Oxford Immunotec Global Plc announced -8.4% year on year sales decline in the third quarter 2020, to $ 19 millions, and underperformed the 10.98% Revenue improvement in the Healthcare sector. Although both In Vitro & In Vivo Diagnostic Substances industry and Healthcare sector posted higher gains than -2.03% overall market increase, Oxford Immunotec Global Plc was trailing overall market in the third quarter.

Company's sequential Revenue growth rate was impressive 233.09% from the second quarter. Average yearly sales growth for Oxford Immunotec Global Plc is 8.29%, while S & P 500's average annual sales growth is 10.19% over the five years, including only Businesses with the third quarter 2020 financial reports.


Growth Rates of OXFD's Income in the third quarter 2020


OXFD Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) 125.41 % 296.2 % -4.59 % -6.93 %
Sequential Operating Income Change (Q3 MRQ) - 149.52 % 64.95 % 61.86 %
Y / Y Operating Income Growth (Q3 TTM) - 8.74 % 41.59 % -9.34 %
Sequential Operating Income Growth (Q3 TTM) - 78.09 % -1.37 % -3.15 %
Operating Income 5 Year Avg. Change - -21.25 % -1.08 % 11.63 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - 497.44 % 5.77 % -12.84 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) - 225.55 % 72.61 % 108.36 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - -7.59 % 1.15 % -29.54 %
Sequential Income from Cont. Ops. Change (Q3 TTM) - 130.19 % 2.99 % -3.86 %
Income from Cont. Ops. 5 Year Avg. Change - - 3.82 % 9.64 %

OXFD Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - 503.04 % 5.77 % -10.3 %
Q / Q Net Income Growth (Q3 MRQ) - 232.1 % 80.49 % 113.34 %
Y / Y Net Income Change (Q3 TTM) - -24.69 % -2.96 % -30.13 %
Sequential Net Income Change (Q3 TTM) - 131.28 % 3.42 % -3.08 %
Net Income 5 Year Avg. Growth - - 3.77 % 11.26 %

OXFD's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - 382.11 % 5.77 % -12.84 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) - 201.94 % 72.61 % 108.36 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - -87.38 % - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) - - - 1.84 %
EPS from Cont. Ops. 5 Year Avg. Growth - - 3.82 % 9.64 %



OXFD EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - 386.63 % 5.77 % -10.3 %
Q / Q EPS Net Growth (Q3 MRQ) - 208.02 % 80.49 % 113.34 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - -86.34 % - -43.72 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) - - - 1.1 %
EPS Net 5 Year Avg. Change - - 3.77 % 11.26 %



Oxford Immunotec Global Plc reported bottom-line of $ -0.01 in the third quarter, compare to $ 0.03 in the same quarter a year ago. In Vitro & In Vivo Diagnostic Substances industry grew by 386.63%, while Healthcare sector increased by 5.77%, and overall market declined by -10.3%.

The Company's sequential EPS growth rate was very impressive 233.09% from the second quarter. Average yearly income per share growth for Oxford Immunotec Global Plc is 8.29%, while S & P 500's average annual income per share growth is 11.26% over the five years, including only Businesses with the third quarter 2020 earnings results.

OXFD Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - 32.97 % 5.83 % -36.86 %
Sequential Free Cash Flow Change (Q3 MRQ) - 64.46 % -5.46 % -38.08 %
Y / Y Free Cash Flow Change (Q3 TTM) - 27.29 % 22.38 % -6.79 %
Sequential Free Cash Flow Change (Q3 TTM) - 0.92 % 1.48 % -7.65 %
Free Cash Flow 5 Year Avg. Change - -2.88 % 8.6 % 16.46 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - -44.36 % -
Sequential Net Cash Flow Change (Q3 MRQ) - - 187.59 % -
Y / Y Net Cash Flow Change (Q3 TTM) - - 65.43 % -
Sequential Net Cash Flow Change (Q3 TTM) - -54.54 % -21.68 % -7.66 %
Net Cash Flow 5 Year Avg. Change - - 65.81 % 280.69 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) 646.41 % -2.07 % 2.34 % -16.87 %
Sequential Capital Expenditures Change (Q3 MRQ) -13.76 % 12.75 % 19.42 % 0.59 %
Y / Y Capital Expenditures Change (Q3 TTM) 310.29 % 0.22 % -6.91 % -15.27 %
Sequential Capital Expenditures Change (Q3 TTM) 38.03 % -1.4 % 0.9 % -4.51 %
Capital Expenditures 5 Year Avg. Change - 27 % 9.99 % 8.03 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.